Our lead development product, EX404, targets PolyCystic Ovarian Syndrome (PCOS) in adolescents and adults.
EffRx received an orphan drug designation (ODD) from FDA for the adolescent PCOS in May 2014. EX113 provides a tangible therapeutic improvement of an already approved medication for Wilson’s Disease.
|Product / Project||Indication||Development Phase|
(buffered effervescent alendronate)
|Osteoporosis||Commercialized in multiple markets|
|EX404 (USA)||Adolescent PCOS (orphan)
|IND with FDA
Phase II / III in development